Home > Boards > US Listed > Biotechs >

MannKind Corp. (MNKD)

Add MNKD Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, Golden_Cross, lakingsphan0427 , $Pistol Pete$
Search This Board: 
Last Post: 5/20/2019 10:53:08 AM - Followers: 409 - Board type: Free - Posts Today: 0


     WEEKLY NUMBERS     http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116919069
Many Afrezza users have reported rapid drops in A1c

Yeah, but in the only clinical trials that compared Afrezza to rapid acting insulins, Afrezza did no such thing.

Straight from the label:

Absolute HgA1c reduction:
Afrezza : 0.21
Rapid I : 0.40

% of patients reducing by 7% or more:
Affreza: 13.8%
Rapid I: 27.1%

And there is your problem. Tweets do not counter clinical trial data.

Afrezza avoids the needle, for sure.But is it better?

It has a faster/narrower spike. BUT, to take advantage of this, the user need to know how to use it.

Perhaps a few users have got it down, and do better. But that does not work for the masses.

MNKD really needs to figure out how to work with the new electronic glucose monitors to solve this issue.        

 p.s. Reading the Mannkind report at FDA.GOV provides plenty of clues why Afrezza is a failure.


About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh) is a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. AFREZZA was approved by the FDA in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of AFREZZA. Sanofi is responsible for global commercial, regulatory and development activities and. MannKind manufactures AFREZZA at its manufacturing facility in Danbury, CT.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

- See more at: http://www.mannkindcorp.com/about-us-overview.htm#sthash.6MYBImtD.dpuf


Alfred E. Mann, Founder (Deceased)

Alfred E. Mann had been one of MNKD's directors since April 1999, Chairman of the Board since December 2001 and  Executive Chairman since January 2015. He also served as our Chief Executive Officer from October 2003 until January 2015.  Mr. Mann has founded and largely funded 14 companies in his career.  Nine were acquired at an overall total of almost $8 billion, and three companies became public.  In addition to MannKind, he is currently involved with:

• Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs;
• Second Sight, which is developing a visual prosthesis to restore sight to the blind; 
• IncuMed, which is developing novel percutaneous seals for various applications; 
• PerQFlo, which is developing drug delivery systems; and
• RoundTrip, which is developing location and identification technology.

In 1993, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. until August 2001 when it was acquired by Medtronic, Inc.  Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of Type 1 diabetes.  Mr. Mann founded and funded Medical Research Group (MRG), a developer of an artificial pancreas.  MRG was also acquired by Medtronic in 2001.  Mr. Mann also founded and served as the Chairman of the Board and Chief Executive Officer of Advanced Bionics Corporation from its founding in 1993 until it was acquired by Boston Scientific Corporation in 2004.  Advanced Bionics developed neurostimulation devices for various neural deficits, including cochlear stimulators.  Previously, Mr. Mann founded and was Chairman of the Board and CEO of Pacesetter Systems, Inc., which developed, manufactured and distributed cardiac pacemakers, from 1972 until 1985 when it was acquired by Siemens, AG.  From 1985 to September 1992, Mr. Mann continued to serve as Chairman and CEO of the successor company, Siemens-Pacesetter, Inc., Pacesetter is now the Cardiac Rhythm Management unit of St. Jude Medical.  Prior to 1972, he was President of Spectrolab, an electro-optical and aerospace systems company, and Heliotek, a semiconductor and electro-optical components manufacturer.  Mr. Mann founded these companies in 1956 and 1960, respectively, sold them to Textron Inc. in 1960 and continued to lead them until 1972, when he left for Pacesetter.  They are now part of the Boeing Company.
Mr. Mann founded and endowed, and from 1985 until 2006 served as Chairman of the Board of Trustees of The Alfred Mann Foundation, a nonprofit research organization devoted to development of advanced medical products in a variety of fields.  Mr. Mann is currently Chairman of the Board of Trustees of the Alfred Mann Institutes at the University of Southern California, Purdue University, and The Technion Institute (Israel), all of these medical research foundations founded and endowed principally by Mr. Mann.  He also serves as a Trustee for the University of Southern California, as a member of the Board of Overseers of the Keck USC School of Medicine, and as the Chairman of the Southern California Biomedical Council, a nonprofit association dedicated to the fostering of the bio-medical industry in the Los Angeles Metropolitan area.  Alfred Mann also serves as a Director of the Nevada Cancer Institute.
Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel).  Mr. Mann is also a member of the National Academy of Engineering.

Ronald Consiglio 

Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge


http://www.mnkd.proboards.com/  A good forum for discussion on Mankind


MannKind Corporation, a development stage company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer. Its lead investigational product candidate, the Technosphere Insulin System, is in phase III clinical trials in the United States, Europe, and Latin America for the treatment of diabetes. This dry powder therapy consists of Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using its proprietary MedTone inhaler. The company is also developing therapies for the treatment of solid tumor cancers. The lead product candidate in this program, MKC1106-PP, which is in phase I clinical trial is intended for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, and prostate carcinomas and melanoma. MannKind was founded in 1991 and is headquartered in Valencia, CA.





Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MNKD News: Statement of Changes in Beneficial Ownership (4) 05/16/2019 04:41:25 PM
MNKD News: Statement of Changes in Beneficial Ownership (4) 05/16/2019 04:31:33 PM
MNKD News: Statement of Changes in Beneficial Ownership (4) 05/16/2019 04:30:17 PM
MNKD News: Statement of Changes in Beneficial Ownership (4) 05/16/2019 04:29:29 PM
MNKD News: Statement of Changes in Beneficial Ownership (4) 05/16/2019 04:28:48 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#31496  Sticky Note $MNKD MannKind Receives $12.5 Million Milestone Payment from $Pistol Pete$ 04/01/19 09:28:51 AM
#27521  Sticky Note From the MNKD proboards -->> TTIME 02/14/18 02:49:38 PM
#31541   Too much "excitement," eh? parkerstar 05/20/19 10:53:08 AM
#31539   MNKD Daily Chart: Golden_Cross 05/17/19 06:28:56 PM
#31538   For the week ending 5/10 WHS 05/17/19 10:52:41 AM
#31536   Looking for a good run tomorrow Mr Breezy 05/16/19 09:07:54 PM
#31535   Good move by MNKD - XenaLives 05/16/19 05:28:52 PM
#31534   Insider buying galore today. 18 insiders aquired bakersson 05/16/19 05:08:51 PM
#31533   News out. Australian Partnership. bakersson 05/16/19 04:54:37 PM
#31531   Go Mnkd Mr Breezy 05/15/19 10:29:40 AM
#31530   $3.00 ++++++ go Mnkd Mr Breezy 05/14/19 06:46:54 PM
#31529   * * $MNKD Video Chart 05-14-2019 * * ClayTrader 05/14/19 05:30:00 PM
#31528   be nice if Mankind sold a position in Afrezza Mr Breezy 05/12/19 10:22:34 AM
#31527   nice..i am loading today Blutribe 05/08/19 02:22:59 PM
#31526   Sold all my position at 1.8995 last month lakingsphan0427 05/08/19 01:58:15 PM
#31525   MNKD OVERSOLD here buying today at 1.31 Blutribe 05/08/19 12:33:23 PM
#31523   shorts dropping off. nice Mr Breezy 05/05/19 06:29:26 PM
#31522   i agree big news coming. buying more tomorrow Mr Breezy 05/05/19 06:27:50 PM
#31521   Must say, I'm disappointed with the stock price Go4itbigtime 05/01/19 10:22:26 AM
#31519   $MNKD 10 days 30' chart $Pistol Pete$ 04/30/19 08:44:06 PM
#31517   $MNKD Daily Chart Golden_Cross 04/24/19 06:32:36 PM
#31514   $MNKD Daily Chart: Golden_Cross 04/20/19 09:23:30 AM
#31512   Commercials failed. Pps still in the dumpster. The SidVicious 04/16/19 09:27:02 AM
#31511   Hoping 700 scripts or better will come in lakingsphan0427 04/06/19 02:56:48 PM
#31510   MNKD Daily Chart: Indicators starting to turn back Golden_Cross 04/06/19 06:54:39 AM
#31509   Do you have the numbers for this week lakingsphan0427 04/05/19 02:53:57 PM
#31507   Big news a coming just waiting on those Hypi 04/04/19 07:32:37 PM
#31506   Got that straight. Profit 04/03/19 06:51:47 AM
#31505   Buy the dip my Friend $Pistol Pete$ 04/02/19 11:11:28 AM
#31503   MNKD Daily Chart: Golden_Cross 04/02/19 04:10:23 AM
#31502   * * $MNKD Video Chart 04-01-2019 * * ClayTrader 04/01/19 05:53:00 PM
#31501   hmmm, back to $1.80! LOL ROFL PIMPL!!!! SidVicious 04/01/19 04:16:43 PM
#31500   Well....it didn’t hurt to go clinical trials again $Pistol Pete$ 04/01/19 12:18:03 PM
#31499   Yeah, India rejected afrezza application and is requiring SidVicious 04/01/19 12:14:59 PM
#31498   News just hit so patience $Pistol Pete$ 04/01/19 09:55:22 AM
#31497   It's really moving up in price with this SidVicious 04/01/19 09:48:00 AM
#31496   $MNKD MannKind Receives $12.5 Million Milestone Payment from $Pistol Pete$ 04/01/19 09:28:51 AM
#31495   MannKind files $500M mixed shelf, warrant exercise prospectus lakingsphan0427 03/29/19 05:56:42 PM
#31494   Prescriptions are still stuck in the mud and SidVicious 03/29/19 08:35:41 AM
#31493   LOL! Keep dreaming. The commercials are not working SidVicious 03/27/19 05:49:54 PM
#31492   Golden Cross BluSkies 03/27/19 10:43:13 AM
#31491   50/200dma cross getting closer daily: Golden_Cross 03/25/19 04:10:24 PM
#31490   * * $MNKD Video Chart 03-25-2019 * * ClayTrader 03/25/19 04:07:22 PM
#31489   News this week? BluSkies 03/25/19 10:13:35 AM
#31488   TIMBER! - MannKind - Afrezza Scripts Still Flat 236T568 03/23/19 04:35:23 PM
#31487   Golden Cross today? Need some GREAT news to BluSkies 03/22/19 08:44:33 AM
#31486   $MNKD Daily Chart $Pistol Pete$ 03/22/19 03:51:23 AM
#31485   Yeah tough with 6 weeks because it takes Hypi 03/21/19 10:23:55 PM
#31484   Hopefully, the commercials will show some fruit tomorrow...Mike Go4itbigtime 03/21/19 01:35:02 PM
#31483   Great looking Chart. Profit 03/21/19 06:58:45 AM
#31482   Yeah shorts aren't going to go away that Hypi 03/20/19 01:20:58 PM
#31481   Big blocks of buys coming in. martind18 03/20/19 09:51:25 AM